John Hackett is responsible for R&D for Abbott's diagnostics business.
The American company, which also designs medical devices (glucose sensors, pacemakers, defibrillators, etc.), is at the heart of the health crisis with its range of Covid tests.
He looks back on the challenges of the sector and on the place taken by the diagnosis thanks to the pandemic.
Read also
Covid-19: towards a more serene end of the year
Le FIGARO.- How has the pandemic transformed our approach to diagnosis?
John HACKETT.
-
Before the Covid, we had never talked so much about tests and diagnostics!
However, 70% of medical decisions are made on the basis of diagnostic elements (blood tests, samples, etc.).
Today, the patient's journey must be conceived in its entirety, from prevention to therapy.
Diagnosis has a key role to play in saving lives and reducing health care costs.
It will be an increasingly digital sector, where algorithms will help define profiles of patients at risk, with more apps and connected tools.
This article is for subscribers only.
You have 84% left to discover.
To cultivate your freedom is to cultivate your curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/PCE7NMB26ZDVRIQX2R26JSNH6A.jpg)
